Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials

Simon Portsmouth, MD, FRCP,1,2 Almasa Bass, PharmD, Roger Echols, MD, FIDSA,3 and Glenn Tillotson, PhD, FIDSA4,5

1Shionogi Inc, Florham Park, New Jersey, USA, 2UCB, Durham, North Carolina, USA, 3ID3C Consultants, Easton Connecticut, USA, 4GST Micro LLC, Richmond, Virginia, USA

Background. For new antibiotics developed to treat antibiotic-resistant Gram-negative infections, the US Food and Drug Administration (FDA) regulatory pathway includes complicated urinary tract infection (cUTI) clinical trials in which the clinical isolates are susceptible to the active control. This allows for inferential testing in a noninferiority study design. Although complying with regulatory guidelines, individual clinical trials may differ substantially in design and patient population. To determine variables that impacted patient selection and outcome parameters, 6 recent cUTI trials that were pivotal to a new drug application (NDA) submission were reviewed.

Methods. This selective descriptive analysis utilized cUTI trial data, obtained from publicly disclosed information including FDA documents and peer-reviewed publications, from 6 new antibiotics developed to treat multidrug-resistant Gram-negative infections: ceftolozane-tazobactam, cefazidime-avibactam, meropenem-vaborbactam, ceferodcol, plazomicin, and fosfomycin. Eravacycline was not approved for cUTI and is not included.

Results. Microbiologic modified intent-to-treat sample size, age, proportions of female patients, acute pyelonephritis (AP), Escherichia coli and other pathogens at baseline, protocol-specified switch to oral antibiotic, and the noninferiority margin were compared. Outcome data included clinical response, microbiologic eradication, and composite outcomes, including a subset of patients with AP.

Conclusions. A study design can follow regulatory guidelines but still have variable populations. The proportion of AP within a study varied greatly and influenced population demographics (age, gender) and baseline microbiology. A smaller proportion of AP resulted in an older patient population, fewer females, less E coli, and lower proportions of patients achieving success. Fluoroquinolones and piperacillin/tazobactam should be reconsidered as active comparators given the high rates of resistance to these antibiotics.

Keywords. acute pyelonephritis; carbapenem resistance; cUTI; study design.

Antibiotic resistance is a global problem that is spreading at an astonishing rate and poses a great threat to humankind. More than 2.8 million people acquire serious infections with bacteria that are resistant to 1 or more of the antibiotics designed to treat those infections annually in the United States [1]. At least 35 000 people die each year as a direct result of these antibiotic-resistant infections, and many others perish from other conditions complicated by an antibiotic-resistant infection [1]. In addition, the estimated economic cost of antibiotic resistance to the American economy ranges from $20 billion in excess direct healthcare costs, with additional costs to society for lost productivity as high as $35 billion a year (2008 dollars) [2, 3]. Some of the antibiotic resistance identified and categorized by the Centers for Disease Control and Prevention (CDC) as either “serious” or “urgent” include the spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter, and multidrug-resistant (MDR) Pseudomonas aeruginosa infections [1]. These same pathogens have been identified by the World Health Organization (WHO)'s global priority list as “Priority 1” and “Critical” [4] The CDC and the WHO have identified the development of new antibiotics as one of the strategies to help address infections due to antibiotic-resistant organisms [1, 4]. Enterobacterales are the most common bacteria causing cUTI, and infections due to MDR organisms within this bacterial family can be characterized as fluoroquinolone-resistant (FQR), broad-spectrum cephalosporin-resistant, or carbapenem-resistant (CR). Although carbapenems can be used to treat FQR- and ESBL-producing organisms, there are limited options for CRE [5, 6]. The mortality associated with CRE infections, including bacteremia, may be as high as 20% to 54.3%, which further underscores the need for better available treatment options [6–9].

One challenge for pharmaceutical companies as they develop new antibiotics to treat MDR or extensive drug-resistant (XDR)
infections is the need for interpretable clinical trial data, which requires inferential (statistical) testing of a prespecified efficacy hypothesis. The acceptable study is a noninferiority design that excludes organisms known to be resistant to the active control treatment. Until the recent approval of antibiotics capable of treating CR pathogens, this feature of equipoise often excluded the very types of infections that the new antibiotics were being developed to treat.

To facilitate the development of new antibiotics to treat MDR/XDR Gram-negative infections, both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have endorsed a streamlined development pathway with limited clinical trial requirements. A single study in cUTI with a less robust noninferiority margin (15%) supported by pharmacokinetic/pharmacodynamic data and a minimum of 300 patients treated with the investigational product (IP) may be sufficient for a “limited use” indication in cUTI.

To further facilitate enrollment of patients into cUTI clinical trials, the FDA and EMA have recently allowed (1) prior antibiotic use for up to 24 hours in a proportion (<25%) of study patients and (2) for investigational antibiotics with only a parenteral formulation and the ability to switch to a noninvestigational oral antibiotic. This results in variability of the timing of the primary efficacy endpoint to a fixed day (usually day 5) when the patient is still receiving the IP, rather than the traditional test of cure (TOC) approximately 1 week after the last dose of the study drug. Another important variable is the selection of the active control antibiotic, which may or may not be suitable for current study patient populations. These differences in treatment regimens and primary endpoints make direct comparison of clinical trials for cUTI more difficult. The intention of this analysis was to highlight the current cross-study differences and to recognize and correct for this variability in future trials.

METHODS

Six recent clinical trials that supported FDA or EMA regulatory review for the indication of cUTI including pyelonephritis have been analyzed in a selected descriptive approach. Data were obtained from publicly disclosed information and the following hierarchy was utilized: (1) US Prescribing Information, (2) FDA Medical Review, and (3) peer-reviewed publications. Acute uncomplicated pyelonephritis (AUP) was defined as pyelonephritis with normal urinary tract anatomy and the presence of clinical signs and symptoms of upper urinary tract involvement. Unless otherwise specified, it was assumed that AP is the same or closely approximated AUP. Two studies, RECAPTURE (ceftazidime-avibactam) and APEKS-cUTI (cefiderocol), included patient self-assessment questionnaires to compare with physician assessment (Patient Symptom Assessment Questionnaire [PSAQ] and Structured Patient Interview [SPI], respectively). Neither were validated, patient-reported outcome instruments.

Complicated UTI is defined as a urinary tract infection with pyuria and a documented microbial pathogen, which is usually accompanied by local and systemic signs and symptoms. These concomitantly occur in the presence of a functional or an anatomic abnormality of the urinary tract or in the presence of catheterization. Acute pyelonephritis and AUP are identified as a subset of cUTI.

RESULTS

Ceftolozane-tazobactam ([TOL-TAZ] ASPECT-cUTI) [10] and ceftazidime-avibactam ([CAZ-AVI] RECAPTURE) [11] trials followed a traditional development plan in which the noninferiority margin was 10%. The remaining 4 investigational studies (meropenem-vaborbactam [MER-VAB], TANGO-1 [12]; plazomycin [PLZ], EPIC [13, 14]; cefiderocol [CFDC], APEKS-cUTI [15]; IV fosfomycin [FOS], ZEUS [16, 17]) were subject to streamlined development “flexibility” and had a noninferiority margin of 15%. Patient populations differed based on the proportion of AP or AUP, which resulted in more females, younger age, higher proportion of *Escherichia coli*, and higher success for the composite endpoint of clinical cure and microbiologic eradication. The percentage of randomized patients with a qualifying bacterial pathogen (≥10^5 colony-forming units/mL) identified at baseline (ie, micro-ITT population) ranged from 64.2% in the EPIC trial to 82.8% in the APEKS-cUTI trial. The gender distribution in the EPIC and APEKS-cUTI trials was almost equivalent, reflecting the lower proportion of subjects with AP or AUP (41.8% and 27%, respectively), compared with the other 4 contemporary cUTI studies in which AP, which is predominantly seen in younger females, often contributed to the majority of study participants. Patient population with AP/AUP ranged from 27% in the APEKS-trial to 82% in the ASPECT-cUTI trial. *Escherichia coli* was the predominant pathogen at baseline in all studies, but it ranged from 62.3% in the APEKS-cUTI trial to 78.6% in the ASPECT-cUTI trial, and it was inversely related to the proportion of AP/AUP. *Pseudomonas aeruginosa* ranged from 0 to 6.2% (Table 1). The proportion of patients with resistance to the control antibiotic of the baseline pathogen varied greatly (2.6%–26.5%) and was related to the choice of the active control antibiotic.

All studies met the prespecified criteria for noninferiority (10% or 15%), and, despite the noninferiority study design, 4 of 6 trials demonstrated statistical superiority for the composite endpoint at TOC, which was driven by better microbiologic eradication at TOC for the investigational drug. Microbiologic eradication at TOC (range, 56.2%–89.5%) was highly variable and considerably lower than eradication at EOT (range, 84.6%–97.9%). Three of the 6 studies permitted switch-to-oral
Table 1. Baseline Demographics and Study Design

| Study Design | ASPECT-cUTI [10] | CAZ/AVI RECAPTURE [11] | TANGO-1 [12] | Epic [13, 14] | APEKS-cUTI [15] | ZEUS [16, 17] |
|-------------|----------------|-------------------------|--------------|--------------|----------------|--------------|
| Safety ITT population (randomized and treated) (N) | 1068 | 1020 | 545 | 609 | 448 | 464 |
| mMITT (N) | 800 | 810 | 374 | 388 | 371 | 362 |
| % of Safety Population | 74.9 | 79.4 | 68.6 | 64.2 | 83.0 | 78.0 |
| Patient Population | | | | | | |
| Female (%) | 74 | 69.8 | 66.0 | 60.0 | 55 | 63.5 |
| Age (mean) | 50.5 | 52.4 | 54.0 | 59.4 | 62 | 49.9 |
| Age ≥65 years (%) | 25 | 31 | 37 | 49.5 | 55 | 34.5 |
| AP/AUP (%) | 82 | 72/62 | 59 | 41.8 | 27 | 53 |
| Pathogens at Baseline | | | | | | |
| Escherichia coli (%) | 78.6 | 73.8 | 64.7 | 67.8 | 62.3 | 73.4 |
| Pseudomonas aeruginosa (%) | 2.9 | 4.7 | 3.7 | 0 | 6.2 | 4.7 |
| Pathogens at baseline resistant to comparator drug (%) | 26.5 | 3.0 | 12.0 | 2.6 | 3.2 | 5.1 |
| Comparator study drug and dose | | | | | | |
| Levofoxacin 750 mg Q24H | | | | | | |
| Doripenem 500 mg Q8H | | | | | | |
| PIP/TAZ 4.5 g Q8H | | | | | | |
| Meropenem 1 g Q8H | | | | | | |
| IMI/CS 1 g Q8H | | | | | | |
| PIP/TAZ 4.5 g Q8H | | | | | | |
| Randomization | 1:1 | 1:1 | 1:1 | 1:1 | 2:1 | 1:1 |
| Switch from IV to PO | No | Yes | Yes | Yes | No | No |
| Duration of IV therapy (median) | 6.7 days (both groups) | 7 days (CAZ/AVI) 8 days (doripenem) | 8 days (both groups) | 6 days (both groups) | 9 days (both groups) | ~7 days |
| Noninferiority margin (%) (FDA) | 10% | 10% | 15% | 15% | 15% | 15% |

Abbreviations: AP, acute pyelonephritis; AUP, acute uncomplicated pyelonephritis; CAZ/AVI, ceftazidime/avibactam; cUTI, complicated urinary tract infection; FDA, US Food and Drug Administration; IMI/CS, imipenem/cilastatin; ITT, intent-to-treat; IV, intravenous; MER/VAB, meropenem/vaborbactam; mITT, microbiologic modified intent-to-treat; NA, not applicable; PIP/TAZ, piperacillin/tazobactam; TOL/TAZ, ceftolozane/tazobactam.
treatment. In studies in which switch-to-oral therapy was not allowed, the duration of therapy of the investigational antibiotic was 7–9 days compared with 6–8 days where oral switch was allowed. The combined clinical response and microbiologic eradication at TOC was generally similar for all investigational drugs, but these varied for the comparator drugs, resulting in considerable treatment differences and demonstration of statistical superiority for the investigational drug in 4 of 6 studies (Table 2). All comparator drugs used in each of the studies used the FDA-approved dosing per indication; however, due to increasing antibiotic resistance, studies in which an FQ (levofloxacin in the ASPECT trial) or PIP/TAZO (in TANGO 1 and ZEUS) enrolled patients with baseline pathogen resistant to the control drug was 26% and 12% and 5.1%, respectively, whereas in studies using a carbapenem as the active control, the proportion enrolled with carbapenem resistance was <4%.

All treatment arms from the 6 studies had rates of microbiological eradication at end of treatment (EOT) exceeding 92%, with the exception of the levofloxacin arm in ASPECT (84%), which reflected the high rates of levofloxacin resistance at baseline. However, at TOC, recurrence of the baseline pathogen was common, reflecting lower overall success at this traditional time point for efficacy analysis. For the composite endpoint of clinical cure and microbiologic eradication, the range was 54.5%–73.2% for the active comparators and 64.7%–81.7% for the investigational antibiotics.

A consistent finding in all studies was the higher composite success and microbiological eradication in patients with AP/AUP compared with overall study population response rate. In addition, in all cases, the response reported with the investigational drug for AP/AUP was higher than the control drug.

**DISCUSSION**

Complicated UTI is defined as a clinical syndrome characterized by pyuria and a documented microbial pathogen, identified either through a urine or blood culture, and accompanied by local and/or systemic signs and symptoms. These may include dysuria, urinary frequency, suprapubic pain, fever, chills, malaise, flank pain, and/or tenderness that occur (1) in the presence of a functional or an anatomical abnormality of the urinary tract or (2) in the presence of catheterization. Patients with infection involving the upper urinary tract, ie, the kidney, are considered to have pyelonephritis. Patients with acute pyelonephritis, regardless of the presence of an underlying urinary tract abnormality, are considered a subset of patients with cUTI [18, 19]. However, these patients are not always well defined in clinical trials. It is notable that all 6 studies reviewed followed the FDA- and EMA-specific criteria for the diagnosis and definition of eradication. Acute pyelonephritis is generally referred to as an acute infection occurring in a patient without host factors defining a cUTI, for example, urinary tract obstruction,
stones, cancer, or bladder catheterization [18, 20]. However, patients with a cUTI may also have involvement of the kidney, thus there are 2 different populations with AP: those with or without host factors constituting cut UTI. In the setting of clinical studies to support new investigational antibiotics, all identified AP as a separate population from cut UTI. Only 1 study, APEKS-cUTI, made a clear distinction between AUP and cUTI with or without pyelonephritis, at the time of randomization. Other studies provided post hoc categorization of AP with or without an anatomic abnormality to qualify as cUTI. Due to this heterogeneity of infection types, cross-study comparisons of efficacy results are compromised because there are several variables that affect the outcomes.

The proportion of a study population that has AUP can influence the outcome because these infections occur in younger patients, usually female, with pathogens more likely to be antibiotic-susceptible E coli, resulting in higher clinical and microbiologic response rates [21]. The high recurrence rate after the EOT in patients with cUTI is not unexpected and is likely due to irreversible host factors defining cUTI such as renal or bladder calculi, cancer, or indwelling bladder catheters, all of which provide a nidus for biofilm-forming pathogens [20].

Based on the comparisons of these recent cUTI clinical trials for new antibiotic approvals, the suitability of fluoroquinolones or piperacillin/tazobactam as comparators should be questioned. Initial patient randomization and treatment occurs before the full identification and susceptibility of the causative pathogen is known. As antibacterial resistance continues to increase, the relevance of some active control treatments should be questioned. With the recent approval of several new antibiotics with activity against FQR-producing, ESBL-producing, and CR Enterobacterales, future studies should consider using one of these agents as the active control. This would allow CR organisms to be enrolled, thus making study recruitment easier and the outcomes more relevant to the current need for new antibiotics.

This analysis of recent cUTI clinical trials has several strengths. All are contemporary randomized, double-blinded prospective studies using similar inclusion or exclusion criteria. All met the prespecified criteria for noninferiority even for the more robust 10% noninferiority margin required for traditional approval. This comparison study does demonstrate the impact of the proportion of AP in the study population on patient demographics, baseline microbiology, and clinical and microbiologic outcomes.

The main weakness of the study is the assumption made defining AP. Only the APEKS-cUTI and the APECT study clearly differentiated AUP from cut UTI with upper tract involvement. However, given the general understanding for what constitutes AP and the evidence from the patient demographics (age, gender) and baseline pathogens, the majority of AP are assumed to be AUP. Limitations in the enrollment of AUP in the clinical trial provide a patient population that is older and more gender equal and may provide a more appropriate population for the treatment of patients with MDR/XDR cUTIs.

CONCLUSIONS

Clinical trials in cUTI, even when they serve the same regulatory and formulary decision-making objectives, are not the same. This review was not intended to demonstrate that any drug was better. Different endpoints and patient populations are influenced by study design (switch to oral) and the proportion of patients with AP. The wide range of AP diagnoses suggests that some studies enrolled more difficult-to-treat patients who are at greater risk of an infection caused by MDR pathogens. Paradoxically, those trials with a lower proportion of AUP were better able to demonstrate a treatment benefit (superiority) for microbiologic eradication for the investigational drug (eg, cefiderocol and plazomicin) in a more clinically challenging situation. Finally, not all antibiotics currently approved for cut UTI are suitable for noninferiority studies in cUTI, given the current high rates of FQR- and ESBL-producing Enterobacterales. It is fortunate that the recent approval of several new antibiotics for cUTI provides a new standard for active control treatment.

Acknowledgments

We thank Dr. Patrick Scoble for editorial support.

Financial support. This study was funded by Shionogi Inc.

Potential conflicts of interest. R. E. is a consultant to Shionogi Inc, S. P. is an employee of Shionogi Inc, G. T. is a consultant to Shionogi Inc, and A. B. is a former employee of Shionogi. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 20 July 2020.

2. The Alliance for the Prudent Use of Antibiotics (APUA). The cost of antibiotic resistance to U.S. families and the health care system. Available at: http://www.tubb.co.edu/med/npap/consumers/personal_home_5_1451036133.pdf. Accessed 29 July 2020.

3. Roberts RR, Hota B, Ahmed I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49:1175–84.  

4. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, development and deployment of new antibiotics. Available at: http://apps.who.int/medicinedocs/documents/s3317en/s3317en.pdf. Accessed 20 July 2020.

5. Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med 2019; doi: 10.1080/00325481.2019.1680052.

6. Alexander EL, Loutit J, Tambarello M, et al. Carbapenem-resistant enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017; 4of063.

7. Tambarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943–50.

8. Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862–72.
9. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20:1170–5.

10. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949–56.

11. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program. Clin Infect Dis 2016; 63:754–62.

12. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 2018; 319:788–99.

13. Achaogen. Antimicrobial Drugs Advisory Committee (AMDAC) Meeting Briefing Book. Plazomicin. South San Francisco, CA: Achaogen, Inc.; 2018.

14. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al.; EPIC Study Group. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med 2019; 380:729–40.

15. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18:1319–28.

16. Kaye KS, Rice LB, Dane A, et al. Fosfomycin for injection (ZTI-01) vs piperacillin-tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2/3 randomized trial. Clin Infect Dis 2019; pii:ciz181.

17. Skarinsky D, Eckburg PB, Das A, Manvelian K, Ellis-Grosse EJ. Per pathogen outcomes from the ZEUS study, a multi-center, randomized, double-blind phase 2/3 study of ZTI-01 (fosfomycin for injection) versus piperacillin-tazobactam (P:T) in the treatment of patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) [poster no. 1833]. 6th Annual IDWeek (San Diego, CA). October 4–8, 2017.

18. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Guidance for industry. 2017. https://www.fda.gov/downloads/Drugs/Guidances/UCM359184.pdf. Accessed September 2020.

19. Johansen TE, Botto H, Çek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIu classification system. Int J Antimicrob Agents 2011; 38:64–70.

20. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Rev. 3 Dec 19, 2018, section 6.1.5. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf. Accessed February 2021.

21. Belyayeva M, Jeong JM. Acute pyelonephritis. In: StatPearls. Treasure Island, Florida: StatPearls Publishing; 2020:2–3.